Identification of novel markers for the diagnosis of malignant pleural mesothelioma

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1033-1042

  Gueugnon, Fabien ^a   Leclercq, Sabrina ^a   Blanquart, Christophe ^a   Sagan, Christine ^b   Cellerin, Laurent ^b   Padieu, Martine ^a   Perigaud, Christian ^b   Scherpereel, Arnaud ^c   Gregoire, Marc ^a  

^a Groupe Cytokines et Récepteurs   (France)

^b CHU de Nantes   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 2; GALECTIN 3; MONOCYTE CHEMOTACTIC PROTEIN 1;

AGED; ARTICLE; CANCER CELL CULTURE; CELL LABELING; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; VALIDATION PROCESS;

EID: 79952766032     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.12.014     Document Type: Article

References (44)

1. Hodgson JT, Darnton A: The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000, 44:565-601
2. Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet 2005, 366:397-408 (Pubitemid 41073959)
3. Beasley MB: Immunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med 2008, 132:1062-1072
4. Ordonez NG: What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007, 38:1-16
5. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008, 3:851-857
6. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008, 85:265-272 (Pubitemid 350265805)
7. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006, 173:1155-1160 (Pubitemid 43726897)
8. Scherpereel A, Lee YC: Biomarkers for mesothelioma. Curr Opin Pulm Med 2007, 13:339-443
9. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13:2928-2935 (Pubitemid 46850705)
10. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, Richards WG, Sugarbaker DJ, Bueno R: Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002, 62:4963-4967 (Pubitemid 34984420)
11. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, Jaklitsch MT, Sugarbaker DJ, Bueno R: Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003, 95:598-605 (Pubitemid 36553506)
12. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY, Richards WG, Sugarbaker DJ, Bueno R: Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005, 11:4406-4414 (Pubitemid 40825631)
13. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R: Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005, 166:1827-1840 (Pubitemid 40734405)
14. Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn BH: Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta 2004, 1688:43-60 (Pubitemid 38366304)
15. Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S: Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004, 10:849-859 (Pubitemid 38198883)
16. Mohr S, Bottin MC, Lannes B, Neuville A, Bellocq JP, Keith G, Rihn BH: Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 2004, 86:13-19 (Pubitemid 38264274)
17. Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB, Saxild HH, Nielsen C, Brunak S, Knudsen S: A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 2002, 3(9):research0048 [Epub 2002 Aug 30]
18. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30:e15
19. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868 (Pubitemid 29003722)
20. Saldanha AJ. Java treeview: extensible visualization of microarray data. Bioinformatics. 2004, 20:3246-3248. Epub doi:10.1093/bioinformatics/ bth349 (Pubitemid 39619217)
21. Conti I, Rollins BJ: CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14:149-154 (Pubitemid 38586739)
22. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM: CCL2 blockade augments cancer immunotherapy. Cancer Res 2010, 70:109-118
23. Califice S, Castronovo V, Van Den Brule F: Galectin-3 and cancer (Review). Int J Oncol 2004, 25:983-992
24. Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A: Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 2009, 71:31-38
25. Greillier L, Roll P, Barlesi F, Robaglia-Schlupp A, Fraticelli A, Cau P, Astoul P: [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study]. Rev Mal Respir 2007, 24:859-867
26. Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD: A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006, 12:5129-5135 (Pubitemid 44453340)
27. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pechoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010, 35:479-495
28. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M: Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006, 12:447-453 (Pubitemid 43166134)
29. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573 (Pubitemid 41434635)
30. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996, 93:136-140 (Pubitemid 26041483)
31. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999, 96:11531-11536 (Pubitemid 29487415)
32. Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, Scherpereel A, Dabouis G, Gregoire M: Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008, 99:590-594 (Pubitemid 351228578)
33. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132:1239-1246 (Pubitemid 47620999)
34. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than Hyaluronic acid in malignant mesothelioma. Clin Biochem 2009, 42:1046-1050
35. Hembruff SL, Jokar I, Yang L, Cheng N: Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010, 12:425-433
36. Roca H, Varsos ZS, Pienta KJ: CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia 2009, 11:1309-1317
37. Vitiello PF, Shainheit MG, Allison EM, Adler EP, Kurt RA: Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett 2004, 91:239-245 (Pubitemid 38296384)
38. Zhang J, Lu Y, Pienta KJ: Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010, 102:522-528
39. Zhang J, Patel L, Pienta KJ: CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010, 21:41-48
40. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008, 100:1464-1476
41. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA, Albelda SM: CCL2 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 2010 doi:10.1165/rcmb.2010-0080OC
42. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007, 62:569-576 (Pubitemid 47056881)
43. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW: A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200
44. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G, Tell G: Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003, 302:545-553 (Pubitemid 36279565)